# US 2026/0209824 A1 · Methods for detection of rare subpopulations of cells and highly purified composition of cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0209824 A1
- Document ID: US20260209824A1
- Status: Published application
- Kind: A1
- Application number: 19/443,119
- Filed: 2026-01-08
- Published: 2026-07-23
- Earliest claimed: 2010-07-23
- Assignees: Astellas Institute for Regenerative Medicine
- Applicants: Astellas Institute for Regenerative Medicine
- Inventors: Irina Klimanskaya; Roger Gay
- Web page: https://patentgrep.com/patent/US20260209824A1

## CPC

- C12Q 1/42: involving phosphatase
- G01N 33/5005: {involving human or animal cells (immunoassay G01N33/56966; immunoassays of protozoa G01N33/56905; protozoa in screening assays C12Q1/025)}
- G01N 33/56966: {Animal cells}
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Methods are provided for detection of a target cell type within a cell population, and compositions are provided comprising cells and an indicator that indicates the number of cells of the target cell type in the cell population. Examples are provided in which these methods are used to detect human embryonic stem cells within a differentiated cell population with exquisite sensitivity. Differentiated cells produced from embryonic stem cells can be characterized by these methods before transplantation into a recipient, thereby providing further assurance of safety.

## Claims

### Claim at position 1

1-100. (canceled)

### Claim 101

A method of producing a population of retinal pigment epithelium (RPE) cells comprising:
(a) generating a preparation of differentiated RPE cells by culturing pluripotent stem cells in vitro for a sufficient duration for RPE cells to appear;
(b) isolating an aliquot of cells from the preparation of differentiated RPE cells;
(c) applying a first stain to the aliquot of cells, wherein the first stain detects alkaline phosphatase activity and comprises an alkaline phosphatase substrate, wherein applying the first stain comprises: (i) contacting the aliquot of cells with a cocktail of antibodies that comprises two or more distinct antibodies, wherein the cocktail of antibodies comprises antibodies that, collectively, specifically bind to two or more of Stage-specific embryonic antigen-3 (SSEA-3), SSEA-4, TRA-1-60, TRA-1-81, Nanog, or Rex-1; and (ii) contacting the aliquot of cells with a secondary antibody that binds to antibodies of the cocktail of antibodies, wherein the secondary antibody is directly or indirectly coupled to alkaline phosphatase; and
(d) examining the aliquot of cells by microscopic observation for the presence of cells stained by the first stain.

### Claim 102 (depends on 101)

The method of claim 101, wherein the method further comprises:
applying a second stain to the aliquot of cells, wherein applying the second stain comprises contacting the aliquot of cells with an antibody that specifically binds to Oct-4, wherein the antibody that specifically binds to Oct-4 is directly or indirectly coupled to a fluorescent label; and
examining the aliquot of cells by microscopic observation for the presence of cells stained by the first stain and the second stain.

### Claim 103 (depends on 101)

The method of claim 101, wherein the aliquot of cells isolated in (b) is cultured in the absence of feeder cells prior to (c).

### Claim 104 (depends on 101)

The method of claim 101, wherein the aliquot of cells isolated in (b) is cultured in a stem cell medium prior to (c).

### Claim 105 (depends on 101)

The method of claim 101, wherein the pluripotent stem cells are human cells.

### Claim 106 (depends on 101)

The method of claim 101, wherein the pluripotent stem cells are selected from the group consisting of: embryonal carcinoma embryonal carcinoma (EC) cells; embryonic stem (ES) cells; and induced pluripotent stem (iPS) cells.

### Claim 107 (depends on 101)

The method of claim 101, wherein the first stain comprises an alkaline phosphatase substrate selected from the group consisting of: napthol AS-BI phosphate; 5-bromo-4-chloro-3-indolyl phosphate (BCIP) and Nitro Blue Tetrazolium (NBT); BCIP reagent and INTX reagent; naphthol AS-BI and fast red violet LB; tetrazolium salts; diazo compounds; and p-Nitrophenylphosphate (pNPP).

### Claim 108

A method of producing a population of retinal pigment epithelium (RPE) cells comprising:
(a) generating a preparation of differentiated RPE cells by culturing pluripotent stem cells in vitro for a sufficient duration for RPE cells to appear;
(b) isolating an aliquot of cells from the preparation of differentiated RPE cells;
(c) applying a first stain to the aliquot of cells, wherein the first stain detects alkaline phosphatase activity and comprises an alkaline phosphatase substrate, wherein applying the first stain comprises: (i) contacting the aliquot of cells with a cocktail of antibodies that comprises antibodies that specifically bind to Stage-specific embryonic antigen-4 and antibodies that specifically bind to TRA-1-81; and (ii) contacting the aliquot of cells with a secondary antibody that binds to antibodies of the cocktail of antibodies, wherein the secondary antibody is directly or indirectly coupled to alkaline phosphatase; and
(d) examining the aliquot of cells by microscopic observation for the presence of cells stained by the first stain.

### Claim 109 (depends on 108)

The method of claim 108, wherein the method further comprises:
applying a second stain to the aliquot of cells, wherein applying the second stain comprises contacting the aliquot of cells with an antibody that specifically binds to Oct-4, wherein the antibody that specifically binds to Oct-4 is directly or indirectly coupled to a fluorescent label; and
examining the aliquot of cells by microscopic observation for the presence of cells stained by the first stain and the second stain.

### Claim 110 (depends on 108)

The method of claim 108, wherein the aliquot of cells isolated in (b) is cultured in the absence of feeder cells prior to (c).

### Claim 111 (depends on 108)

The method of claim 108, wherein the aliquot of cells isolated in (b) is cultured in a stem cell medium prior to (c).

### Claim 112 (depends on 108)

The method of claim 108, wherein the pluripotent stem cells are human cells.

### Claim 113 (depends on 108)

The method of claim 108, wherein the pluripotent stem cells are selected from the group consisting of: embryonal carcinoma embryonal carcinoma (EC) cells; embryonic stem (ES) cells; and induced pluripotent stem (iPS) cells.

### Claim 114 (depends on 108)

The method of claim 108, wherein the first stain comprises an alkaline phosphatase substrate selected from the group consisting of: napthol AS-BI phosphate; 5-bromo-4-chloro-3-indolyl phosphate (BCIP) and Nitro Blue Tetrazolium (NBT); BCIP reagent and INTX reagent; naphthol AS-BI and fast red violet LB; tetrazolium salts; diazo compounds; and p-Nitrophenylphosphate (pNPP).

### Claim 115

A method of producing a population of retinal pigment epithelium (RPE) cells comprising:
(a) generating a preparation of differentiated RPE cells by culturing pluripotent stem cells in vitro in a differentiation medium for a sufficient duration for RPE cells to appear;
(b) isolating an aliquot of cells from the preparation of differentiated RPE cells and culturing the aliquot of cells in a stem cell medium and in the absence of feeder cells;
(c) applying a first stain to the aliquot of cells, wherein the first stain detects alkaline phosphatase activity and comprises an alkaline phosphatase substrate, wherein applying the first stain comprises: (i) contacting the aliquot of cells with a cocktail of antibodies that comprises antibodies that specifically bind to Stage-specific embryonic antigen-4 and antibodies that specifically bind to TRA-1-81; and (ii) contacting the aliquot of cells with a secondary antibody that binds to antibodies of the cocktail of antibodies, wherein the secondary antibody is directly or indirectly coupled to alkaline phosphatase; and
(d) applying a second stain to the aliquot of cells, wherein applying the second stain comprises contacting the aliquot of cells with an antibody that specifically binds to Oct-4, wherein the antibody that specifically binds to Oct-4 is directly or indirectly coupled to a fluorescent label;
(e) examining the aliquot of cells by microscopic observation for the presence of cells stained by the first stain and the second stain.

### Claim 116 (depends on 115)

The method of claim 115, wherein the pluripotent stem cells are human cells.

### Claim 117 (depends on 115)

The method of claim 115, wherein the pluripotent stem cells are selected from the group consisting of: embryonal carcinoma embryonal carcinoma (EC) cells; embryonic stem (ES) cells; and induced pluripotent stem (iPS) cells.

### Claim 118 (depends on 115)

The method of claim 115, wherein the first stain comprises an alkaline phosphatase substrate selected from the group consisting of: napthol AS-BI phosphate; 5-bromo-4-chloro-3-indolyl phosphate (BCIP) and Nitro Blue Tetrazolium (NBT); BCIP reagent and INTX reagent; naphthol AS-BI and fast red violet LB; tetrazolium salts; diazo compounds; and p-Nitrophenylphosphate (pNPP).
